Senolytics are a class of drugs that selectively clear senescent cells, which can help to reverse aging and keep you feeling ...

Senolytics—a class of drugs that reduce chronic inflammation and tissue damage in aging cells—are shown to eliminate 30% to 70% of "zombie" cells in the body. These zombie cells, known as senescent ...

SEATTLE -- A drug targeting senescent cells in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) produced mixed outcomes in two separate clinical trials. The 48-week ...

NEW YORK CITY -- An investigational drug targeting senescent cells achieved sustained improvement in visual acuity in patients with diabetic macular edema (DME) or neovascular age-related macular ...

Senolytics are an emerging class of drugs designed to target zombie-like cells that have stopped dividing and build up in the body as we age, and the past few years have seen some exciting discoveries ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — A senolytic therapy represents a novel approach to treating diabetic macular edema and ...

A new research paper was published by Aging (Aging-US) on January 8, 2025, in Volume 17, Issue 1, titled "Senolytic agent ABT-263 mitigates low- and high-LET radiation-induced gastrointestinal cancer ...

MIAMI, Sept. 24, 2025 /PRNewswire/ -- Immorta Bio, Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," today announced the filing of a U.S.

MIAMI, March 5, 2025 /PRNewswire/ -- Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today acceptance of its poster presentation at the upcoming Society for Immunotherapy of ...

Researchers from Juntendo University, Japan examine the molecular mechanisms underlying the senolytic or senescent cell removal effects of the the sodium glucose co-transporter 2 inhibitor and its ...

In a recent study published in Nature Medicine, researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and ...